Obtenga las últimas noticias sobre las acciones de Biofrontera con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de BFRI

Últimas noticias sobre

BIOFRONTERA INC

Biofrontera

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.

Quantum,Computing,Concept,,Quantum,Mechanics,,Advanced,Technology,,Artificial,Intelligence,And

AMAT

BFRI

CISO

CLIK

DOCS

GLOB

HCTI

IXHL

KLRS

LGPS

ORGN

PTIX

QUBT

SATL

SPCE

TSSI

TVTX

Descubre las acciones que destacan en el premercado de EE. UU.: Quantum Computing sube tras superar expectativas, mientras otras caen.

Acciones de Quantum Computing (QUBT) se disparan un 12%; aquí están 20 acciones que se mueven en premercado

Biofrontera Inc

Press Releases

BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG

Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025

Biofrontera Inc. Appoints George Jones as Chief Commercial Officer

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update

Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk

Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program

Penny Stocks

Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG

BFRIW

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Artelo Biosciences

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Athira Pharma

Cocrystal Pharma

Curanex Pharmaceuticals Inc - Common Stock

Curanex Pharmaceuticals

Evoke Pharma

Gelteq

Hoth Therapeutics

Impact BioMedical

IM Cannabis

Jaguar Health

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lipocine

Lyra Therapeutics

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals

ProPhase Labs

Pulmatrix

Q/C Technologies

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

TherapeuticsMD

VYNE Therapeutics

cbdMD

Benchmark

Comments

Biofrontera Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL